Short explainers, honestly labelled.

1. A molecular report is a starting point, not the whole clinical picture.
2. The question: what matters for this cancer and this patient?
3. Six layers: CloneTrace, PhenoMap, ImmunoLens, SynerGX, TrialGraph and AccessMatch.
4. Structured review and clinician discussion.
5. Evidence organised. Uncertainty stated. The treating clinician retains the decision.

Draft narration: A molecular report can list many findings. POAS helps organise the findings into a structured evidence review. It examines molecular context, relevant biomarkers, therapeutic evidence, clinical-trial opportunities and treatment-access considerations, while recording important limitations. The purpose is not to automate a prescription. It is to support the treating clinician with a clearer view of the evidence.

1. When a case raises a difficult question, structure matters.
2. Case question, diagnosis and stage, pathology, treatment history, imaging and molecular reports.
3. A multidisciplinary discussion, filmed only with consenting staff or actors.
4. Documented considerations and questions for the treating oncologist.
5. Review supports the decision. Clinical ownership remains with the treating doctor.

Draft narration: An MTB review starts with a defined clinical question and the information available for that case. Relevant specialists review the context together, discuss the evidence and uncertainty, and document considerations within the agreed scope. The review can support further clinical discussion, but it does not guarantee a particular recommendation or outcome.

1. A hospital may need oncology capability beyond what is available in-house.
2. Assess the gap, define scope, agree responsibilities, verify staffing, facility and protocols.
3. A model service map: review and MTB, day care and infusion, complementary services that are confirmed.
4. Defined scope. Clear responsibilities. Partnership built around real capability.

Draft narration: KPCIRC works with hospitals and nursing homes to explore defined oncology service arrangements. The starting point is your institution’s needs, existing capabilities and service gaps. Scope, clinical responsibilities, staffing, facilities and protocols are agreed before any service is represented as available.

1. A clear clinical question makes a case review more useful.
2. Checklist: diagnosis and stage, histopathology, molecular report, imaging summary, prior treatment and response, the question.
3. The approved submission form, demonstrated with dummy data only.
4. Acknowledgement, completeness check, then confirmation of scope and timing.

Draft narration: Before submitting a case, gather the relevant clinical summary, pathology, molecular results, imaging information and treatment history. State the question you need the review to address. Use the approved submission route and never place identifiable patient information into an unapproved channel.

1. A little preparation can help you use your appointment well.
2. A folder with diagnosis, pathology, imaging, blood tests, molecular reports and a treatment timeline.
3. Three prompts: what is known, what remains uncertain, what should we discuss next?
4. Bring your questions. Your treating team remains central.

Draft narration: If you are preparing for a consultation or second opinion, bring your available reports, imaging, treatment history and a list of questions. It can help to write down your concerns in advance and bring someone you trust. The required information depends on the service, so contact KPCIRC if you are unsure what to provide.

1. Family history can raise questions. It does not tell the whole story by itself.
2. A simplified, fictional family-history conversation.
3. Counselling topics: why testing is considered, what a result may and may not mean, family implications.
4. Assess history, discuss options, decide whether testing is appropriate, interpret results in context.

Draft narration: Inherited cancer risk assessment begins with personal and family history. Genetic counselling helps explain why a test may be considered, what results can and cannot tell you, and what implications they may have. Testing is not automatically the right first step for everyone; the appropriate pathway depends on clinical assessment.

1. Understanding Cancer. Transforming Care.
2. POAS: structured interpretation of existing molecular reports.
3. MTB: multidisciplinary review of selected cases.
4. Institutional support, defined by real capability.
5. Cancer care, genetics and selected supportive services. The treating doctor leads; KPCIRC supports.

1. Pre-visit checklist: clinical order, history, relevant tests, medicine and site confirmation.
2. Indicative session bands: up to 2 hours, 2–4 hours, 4–6 hours, more than 6 hours. The protocol determines actual duration.
3. Administration, protocol-directed observation, escalation and documented discharge.
4. Confirmed scope. Trained team. Site readiness.

Draft narration: KPCIRC is developing defined day-care and infusion pathways around the prescribed treatment, the patient’s clinical needs and the capability of the specific site. Session bands are planning guides, not guarantees.

1. Certain prescribed measures can reduce a defined treatment-related risk for selected regimens or patients.
2. Examples: prescribed antiemetic support, protocol-directed hydration, premedication for a defined reaction risk, extended observation.
3. Some measures are oral or injectable, not infusions. All need a clinical order and protocol.
4. No universal cancer-prevention infusion. Clinical assessment first.

Draft narration: Some treatments need regimen-specific supportive measures or observation to reduce a known treatment-related risk. The responsible clinician decides what is appropriate, and the route may be oral, injection or infusion. KPCIRC does not promote general infusions as cancer prevention.

1. Search by name and filter by verified service areas.
2. Open a profile to see the approved biography and areas of work.
3. Profiles show approved public information; appointment availability must be confirmed.